BioSpace News Archive

Four studies presented during the 65th American Society of Hematology Annual Meeting and Exposition examine how demographics and other characteristics of patients and researchers play into inequities in health outcomes in the context of blood cancers.

Adaptive Biotechnologies Corporation announced new data demonstrating the expanding use of Adaptive’s next-generation sequencing -based clonoSEQ® test in assessing minimal residual disease in blood cancer patient care and in clinical trials.

Genentech, a member of the Roche Group, announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors.

X4 Pharmaceuticals announced the presentation of additional preliminary data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without concurrent treatment with injectable granulocyte-colony stimulating factor in people diagnosed with idiopathic, cyclic, or congenital neutropenia.

Century Therapeutics announced the presentation of initial clinical data from a single-patient case study which Century believes support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits at the 65th American Society of Hematology Annual Meeting and Exposition, being held December 9-12 in San Diego.

Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.

The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight infections by making proteins that remove germs.

FibroGen, Inc. announced the presentation of efficacy and safety data from MATTERHORN, a Phase 3 clinical study of roxadustat for the treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes at the 65th American Society of Hematology Annual Meeting and Exposition being held in San Diego, California December 9 - 12, 2023.

Orca Bio announced positive new data that suggest its investigational high-precision cell therapies, Orca-T and Orca-Q, have the potential to deliver improved clinical outcomes across different age ranges, donor types and conditioning regimens relative to existing standard of care allogeneic hematopoietic stem cell transplants.

Pfizer Inc. presented results from the pivotal Phase 3 BASIS clinical trial evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII or Factor IX.